Cargando…

Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study

BACKGROUND AND AIM: Disproportionality analysis is traditionally used in spontaneous reporting systems to generate working hypotheses about potential adverse drug reactions: the so-called disproportionality signals. We aim to map the methods used by researchers to assess and increase the validity of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fusaroli, Michele, Salvo, Francesco, Bernardeau, Claire, Idris, Maryam, Dolladille, Charles, Pariente, Antoine, Poluzzi, Elisabetta, Raschi, Emanuel, Khouri, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442263/ https://www.ncbi.nlm.nih.gov/pubmed/37421568 http://dx.doi.org/10.1007/s40264-023-01329-w

Ejemplares similares

Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances
por: Khouri, Charles, et al.
Publicado: (2021)

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
por: Raschi, Emanuel, et al.
Publicado: (2020)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2021)

Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal
por: Raschi, Emanuel, et al.
Publicado: (2022)

Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry
por: Aiello, Valeria, et al.
Publicado: (2021)

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2022)

Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People
por: Lunghi, Carlotta, et al.
Publicado: (2022)

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

PSAT122 The Changing Face of Drug-Induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Dalmazi, Guido D, et al.
Publicado: (2022)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Stroke, Migraine and Triptans: From Bedside to Bench
por: Raschi, Emanuel, et al.
Publicado: (2016)

The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project
por: Raschi, Emanuel, et al.
Publicado: (2015)

Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2023)

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
por: Gatti, Milo, et al.
Publicado: (2020)

Recurrence of pericarditis after influenza vaccination: a case report and review of the literature
por: Mei, Riccardo, et al.
Publicado: (2018)

Understanding the variability of pharmaco‐epidemiological studies assessing the risk of appendicitis with mRNA COVID‐19 vaccines
por: Jambon‐Barbara, Clement, et al.
Publicado: (2022)

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
por: Raschi, Emanuel, et al.
Publicado: (2018)

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
por: Gatti, Milo, et al.
Publicado: (2021)

Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis
por: Hlavaty, Alex, et al.
Publicado: (2022)

Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
por: Poluzzi, Elisabetta, et al.
Publicado: (2014)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
por: Salvo, Francesco, et al.
Publicado: (2016)

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
por: Gatti, Milo, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase(®) Spontaneous Reporting System
por: Noseda, Roberta, et al.
Publicado: (2022)

Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey
por: Girardi, Anna, et al.
Publicado: (2014)

Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
por: Girardi, Anna, et al.
Publicado: (2015)

Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions
por: Iommi, Marica, et al.
Publicado: (2020)

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
por: Sisi, Monia, et al.
Publicado: (2022)

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
por: Raschi, Emanuel, et al.
Publicado: (2023)

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
por: Poluzzi, Elisabetta, et al.
Publicado: (2013)

Disproportional Representation of Primates in the Ecological Literature
por: Heymann, Eckhard W., et al.
Publicado: (2013)

The Induction of Premature Labour in Cases of Disproportion
por: Nicholson, H. Oliphant
Publicado: (1922)

Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database
por: Gastaldon, C., et al.
Publicado: (2023)

Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Poluzzi, Elisabetta, et al.
Publicado: (2015)

Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database
por: Swart, Floor, et al.
Publicado: (2020)

Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase
por: Calapai, Fabrizio, et al.
Publicado: (2023)

The validity of the viscero‐abdominal disproportion ratio for type of surgical closure in all fetuses with an omphalocele
por: Peters, Nina C.J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9em46rf80pmuqam7k8s246b4sj